Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

Prognostic Impact of Gastrointestinal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Kasouha, Nicola Lehners, Katharina Kriegsmann, MD MBA, Gerlinde Egerer, Anthony D Ho, Mathias Witzens-Harig, MD

Blood (2018) 132 (Supplement 1): 5400.

https://doi.org/10.1182/blood-2018-99-117125

Published: 2018

Journal Articles

Prognostic Impact of Extranodal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Kasouha, Nicola Lehners, MD, Katharina Kriegsmann, MD MBA, Gerlinde Egerer, Anthony D. Ho, Mathias Witzens-Harig, MD MHBA

Blood (2017) 130 (Supplement 1): 2855.

https://doi.org/10.1182/blood.V130.Suppl_1.2855.2855

Published: 2017

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Georg Hess, MD, Wagner Karola, Paul LaRosee, MD, Ulrich Keller, Johannes Atta, Mathias Witzens-Harig, MD, Anne Crombé, Christoph Medler, Peter Borchmann, MD, Ulrich Bitz, MD, Christian Lerchenmüller, MD, Matthias Theobald, MD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 2977.

https://doi.org/10.1182/blood.V128.22.2977.2977

Published: 2016

Journal Articles

Identification of Novel Immune-Checkpoint Molecules on Multiple Myeloma Cells Using a High-Throughput Discovery Platform

Valentina Volpin, Till Michels, Antonio Sorrentino, Dirk Hose, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Philipp Beckhove, Mathias Witzens-Harig, MD

Blood (2016) 128 (22): 380.

https://doi.org/10.1182/blood.V128.22.380.380

Published: 2016

Journal Articles

Addition of Rituximab to CHOP-like Chemotherapy Improves Survival in Patients with Primary Mediastinal B-Cell Lymphoma Independent of IPI Risk Category

Katharina Lisenko, MD, Gerrit Dingeldein, Martin Cremer, MD, Mark Kriegsmann, Anthony D. Ho, MD, Michael Rieger, MD, Mathias Witzens-Harig, MD

Blood (2016) 128 (22): 4223.

https://doi.org/10.1182/blood.V128.22.4223.4223

Published: 2016

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Georg Hess, MD, Andreas Hüttmann, MD, Reinhard Marks, MD, Mathias Witzens-Harig, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, Georg Lenz, MD, Christiane Pott, Annegret Kuhn, MD, Christian Ruckes, Matthias Theobald, MD, Ulrich Keller

Blood (2016) 128 (22): 5392.

https://doi.org/10.1182/blood.V128.22.5392.5392

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

A Single Center Comparison Between Two Different Apheresis Systems for Peripheral Blood Stem Cell Collections

Katharina Lisenko, MD, Thomas Bruckner, PhD, Michael Hundemer, MD, Anita Schmitt, MD, Joe Puthenparambil, MD, Petra Pavel, MD, Jens Hillengass, MD, Mathias Witzens-Harig, MD, Hartmut Goldschmidt, MD, Anthony D Ho, MD, Patrick Wuchter, MD

Blood (2015) 126 (23): 1900.

https://doi.org/10.1182/blood.V126.23.1900.1900

Published: 2015

Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Blood (2015) 126 (23): 469.

https://doi.org/10.1182/blood.V126.23.469.469

Published: 2015

Journal Articles

Analysis of Prognostic Factors and Outcome of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract

Nicola Lehners, MD, Isabelle Kraemer, MD, Ronald Koschny, MD, Gerlinde Egerer, MD, Anthony D. Ho, MD, Mathias Witzens-Harig, MD

Blood (2015) 126 (23): 3964.

https://doi.org/10.1182/blood.V126.23.3964.3964

Published: 2015

Journal Articles

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

Georg Hess, MD, Ulrich Keller, Johannes Atta, Ulrich Bitz, MD, Christian Lerchenmueller, Wagner Karola, Christoph Medler, Christian Ruckes, Mathias Witzens-Harig, MD, Kai Huebel, Paul LaRosee, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 3930.

https://doi.org/10.1182/blood.V126.23.3930.3930

Published: 2015

Journal Articles

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Georg Hess, MD, Simon Rule, MD, Wojciech Jurczak, Mats Jerkeman, MD PhD, Rodrigo Santucci, MD, Chiara Rusconi, MD, Dolores Caballero, Cristina M. Joao, MD PhD, Mathias Witzens-Harig, MD, Isabelle Bence-Bruckler, MD FRCPC, Seok-Goo Cho, Nibedita Bandyopadhyay, PhD, Jenna Goldberg, MD, John Bothos, PhD, Christopher Enny, BS, Jessica Vermeulen, MD PhD, Shana Traina, PhD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 1542.

https://doi.org/10.1182/blood.V126.23.1542.1542

Published: 2015

Journal Articles

Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Katharina Lisenko, MD, Fabienne McClanahan, MD PhD, Tilman Schöning, MD, Mark-Alexander Schwarzbich, MD, Martin Cremer, MD, Tobias Dittrich, MD, Anthony D. Ho, MD, Mathias Witzens-Harig, MD

Blood (2015) 126 (23): 1506.

https://doi.org/10.1182/blood.V126.23.1506.1506

Published: 2015

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Mathias Witzens-Harig, MD, Ulrich Keller, Andreas Viardot, MD, Christian Buske, MD, Anne Crombé, Elisabeth Hoenig, Julia Meissner, MD, Anthony D Ho, MD, Reinhard Marks, Martin H. Dreyling, MD PhD, Georg Hess, MD

Blood (2015) 126 (23): 2727.

https://doi.org/10.1182/blood.V126.23.2727.2727

Published: 2015

Journal Articles

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Gilles Salles, MDPhD, Sami Bousseta, Bernice Oberman, Carmit Rubin, Marinus H.J. van Oers, MD PhD, Catherine Fortpied, Msc, Ruth Pettengell, MD, Peter Dreger, MD, Mathias Witzens-Harig, MD, Umberto Vitolo, MD, Andrea Evangelista, Maria Gomes da Silva, Hailun Li, Laurence Freedman, PhD, Thomas M Habermann, MD, Ofer Shpilberg, MD

Blood (2014) 124 (21): 4462.

https://doi.org/10.1182/blood.V124.21.4462.4462

Published: 2014

Journal Articles

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Justin Hasenkamp, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Witzens-Harig, MD, Lutz Uharek, MD, Martin Gramatzki, MD, Michael Pfreundschuh, Gerald Wulf, MD, Lorenz H. Truemper, MD PhD, Norbert Schmitz, MD, Bertram Glass, MD

Blood (2014) 124 (21): 3986.

https://doi.org/10.1182/blood.V124.21.3986.3986

Published: 2014

Journal Articles

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Eric R Rosenbaum, MD MPH, Patrick Wuchter, MD, Michael Hundemer, MD, Petra Pavel, MD, Mathias Witzens-Harig, MD, Hartmut Goldschmidt, MD, Bart Barlogie, MD PhD, Anthony Ho, MD, Michele H. Cottler-Fox, MD

Blood (2014) 124 (21): 2458.

https://doi.org/10.1182/blood.V124.21.2458.2458

Published: 2014

Journal Articles

Rituximab, Age and High Dose Therapy Followed By Autologus Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-Lymphoma

Michael Madle, Isabelle Herth, Nicola Lehners, MD, Mark-Alexander Schwarzbich, MD, Patrick Wuchter, Gerlinde Egerer, MD, Anthony D. Ho, Mathias Witzens-Harig, MD

Blood (2014) 124 (21): 1727.

https://doi.org/10.1182/blood.V124.21.1727.1727

Published: 2014

NARROW

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Prognostic Impact of Gastrointestinal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Prognostic Impact of Extranodal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

Identification of Novel Immune-Checkpoint Molecules on Multiple Myeloma Cells Using a High-Throughput Discovery Platform

Addition of Rituximab to CHOP-like Chemotherapy Improves Survival in Patients with Primary Mediastinal B-Cell Lymphoma Independent of IPI Risk Category

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

A Single Center Comparison Between Two Different Apheresis Systems for Peripheral Blood Stem Cell Collections

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Analysis of Prognostic Factors and Outcome of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract

Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Minimal Renal Toxicity after Rituximab DHAP with a Modified Cisplatin Application Scheme in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL)

Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control

Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols

Rituximab, Age and High Dose Therapy Followed By Autologus Stem Cell Transplantation Are Independent Prognostic Factors for Survival in the First Line Treatment of Primary CNS-Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only